Vivus Beefs Up Qsymia Efforts As Eisai Prepares To Launch Belviq
This article was originally published in The Pink Sheet Daily
The obesity drug market will see substantial commercial investment in the second half of 2013. Vivus is planning its first DTC advertising for Qsymia and continuing its search for a big pharma partner, while Eisai/Arena have been cleared by the Drug Enforcement Agency to launch Belviq.
You may also be interested in...
The obesity pill will be priced at a slight premium to Vivus’ rival drug Qsymia, but Arena CEO says the amount patients will actually pay will vary based on coupon and rebate programs.
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.
Qsymia will launch through certified mail-order pharmacies, but FDA has asked the sponsor to look for ways to expand into the retail space with pharmacies that can meet requirements for distributing patient risk information and keeping track of prescribers.